pSivida announces Iluvien receives FDA priority review for treatment of diabetic macular edema.

pSivida Corp announced that its licensee, Alimera Sciences has been notified that the US Food and Drug Administration (FDA) has granted Priority Review status for the New Drug Application (NDA) filed for Iluvien for the treatment diabetic macular edema (DME). The news regarding priority review follows the submission of the Marketing Authorization Application to the Medicines and Healthcare products Regulatory Agency in the UK in Jul 2010. Applications have also been submitted to regulatory agencies in Austria, France, Germany, Italy, Portugal and Spain. Filing in Canada is expected to take place in Sep 2010. …